Problems come joined at the hip with opportunities. Thermo Fisher Scientific (NYSE: TMO) has definitely found that to be the case with the COVID-19 pandemic. The company’s growth has accelerated and its stock has soared over the last 12 months thanks primarily to coronavirus testing.
That momentum should remain intact after Thermo Fisher reported its fourth-quarter and full-year 2020 results before the market opened on Monday. Here are the highlights from the company’s Q4 update.